SERA Stock Overview
A women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Sera Prognostics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.12 |
52 Week High | US$12.36 |
52 Week Low | US$1.52 |
Beta | 1.04 |
11 Month Change | -12.32% |
3 Month Change | -20.18% |
1 Year Change | 295.56% |
33 Year Change | -31.54% |
5 Year Change | n/a |
Change since IPO | -40.17% |
Recent News & Updates
Recent updates
We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn
Jul 19Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Mar 24Sera Prognostics: The Pregnancy Company On A Hot Streak
Jan 10Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?
Oct 03We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth
Jun 15We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate
Feb 16We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Shareholder Returns
SERA | US Biotechs | US Market | |
---|---|---|---|
7D | -3.3% | -2.1% | -1.9% |
1Y | 295.6% | 13.4% | 20.9% |
Return vs Industry: SERA exceeded the US Biotechs industry which returned 14% over the past year.
Return vs Market: SERA exceeded the US Market which returned 22.7% over the past year.
Price Volatility
SERA volatility | |
---|---|
SERA Average Weekly Movement | 10.2% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SERA's share price has been volatile over the past 3 months.
Volatility Over Time: SERA's weekly volatility has decreased from 26% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 56 | Zhenya Lindgardt | seraprognostics.com |
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
Sera Prognostics, Inc. Fundamentals Summary
SERA fundamental statistics | |
---|---|
Market cap | US$245.26m |
Earnings (TTM) | -US$31.53m |
Revenue (TTM) | US$107.00k |
2,220x
P/S Ratio-7.5x
P/E RatioIs SERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SERA income statement (TTM) | |
---|---|
Revenue | US$107.00k |
Cost of Revenue | US$105.00k |
Gross Profit | US$2.00k |
Other Expenses | US$31.54m |
Earnings | -US$31.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.95 |
Gross Margin | 1.87% |
Net Profit Margin | -29,471.96% |
Debt/Equity Ratio | 0% |
How did SERA perform over the long term?
See historical performance and comparison